<DOC>
	<DOCNO>NCT01378962</DOCNO>
	<brief_summary>This single-arm , open-label study evaluate efficacy safety Tarceva ( erlotinib ) patient locally advanced metastatic non-small cell lung cancer . Patients receive daily oral dos 150 mg Tarceva . The anticipated time study treatment 12 month .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Patients With Locally Advanced Metastatic Non-Small Cell Lung Cancer ( TRIGGER )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /=18 year age Locally advance metastatic nonsmall cell lung cancer Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; /=12 week Adequate hematological , liver , kidney function Previous therapy epidermal growth factor receptor metastatic disease Treatment investigational drug 3 week enrollment History neoplasm Patients symptomatic cerebral metastasis Unstable systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>